

## CONSUMER STAPLES

Q3FY24 Preview

12 January 2024

**Delayed rural recovery to hurt volume growth**

- Q3FY24 presented weak demand trends like the previous quarter due to subdued volume recovery
- General trade continues to witness growth headwinds; regional competition remained elevated during Q3
- Expect sustained margin expansion to support earnings growth; prefer NEST, ITC and DABUR

**Vikrant Kashyap**  
 research@bobcaps.in

**Sluggish demand to keep topline growth muted:** We expect revenue growth for consumer staples companies under our coverage to remain muted in the October-December quarter as the demand environment was weak – like that of the preceding quarter. We expect modest low-to-mid-single-digit growth during Q3FY24 as volume recovery has been relatively slower than expected. Early commentary from key players, including DABUR, GCPL and MRCO, indicates low-to-mid-single-digit volume growth for the quarter. In our view, some volume recovery will be visible in Q4FY24 owing to a strong wedding calendar and increased government spending on account of the upcoming general elections.

**Rural volume growth continues to lag behind urban markets:** Initial commentary suggests growth in rural markets has remained muted during Q3FY24, as higher inflation and impact of uneven rainfall continued to dampen sentiments. Urban markets remained steady and are growing faster than rural centres. During our channel checks in India's **southern** and **eastern** regions, we observed that volume growth in general trade remains muted, but modern trade and e-commerce continue to do well. In e-commerce, most of the growth is coming from quick commerce.

**Expect sustained margin expansion:** We expect continued gross margin expansion for most consumer companies on a YoY basis in Q3 due to the moderation in prices of key commodities. Companies have stepped up their A&P spends to counter lost volumes and to raise brand equity, which is likely to result in double-digit growth in operating profit.

**Sector outlook neutral:** We believe new product launches, increased market penetration, higher capex and premiumisation will continue to fuel growth for consumer staples players in the medium-to-long term. However, near-term headwinds, including delayed rural recovery, stress in general trade and intense regional competition, are likely to impact the Q3 performance for most players. However, despite expected muted volume and value growth, gross margins are forecast to improve YoY, likely resulting in double-digit earnings growth for staples players. We prefer NEST (TP Rs 2,826, BUY), ITC (TP Rs 523, BUY), and DABUR (TP Rs 669, BUY).

**Recommendation snapshot**

Ticker	Price	Target	Rating
BRIT IN	5,137	5,844	BUY
DABUR IN	552	669	BUY
HUVR IN	2,536	3,069	BUY
ITC IN	463	523	BUY
MRCO IN	530	646	BUY
NEST IN	2,557	2,826	BUY
ZYWL IN	1,643	1,556	HOLD

Price &amp; Target in Rupees | Price as of 11 Jan 2024



## Company-wise estimates

**Fig 1 – BRIT**

(Rs mn)	Q3FY24E	Q2FY24	Q3FY23	QoQ (%)	YoY (%)	Remarks
Revenue	43,982	44,329	41,968	(0.8)	4.8	We expect BRIT to report subdued revenue growth of 4.8% YoY during Q3FY24 on account of competition from regional players, which could impact volume recovery, and price cuts taken by the company in the recent past. Biscuits as a category remained resilient despite overall weakness in consumer sentiment. Gross margin is likely to remain muted YoY. Management commentary on demand and competition remain key monitorables.
Gross Profit	19,264	19,011	18,321	1.3	5.1	
Gross Profit Margin (%)	43.8	42.9	43.7	90bps	10bps	
EBITDA	8,972	8,724	8,176	2.8	9.7	
EBITDA Margin (%)	20.4	19.7	19.5	70bps	90bps	
Adj. PAT	6,132	5,876	5,568	4.4	10.1	
Adj. PAT Margin (%)	13.9	13.3	13.3	64bps	60bps	

Source: Company, BOBCAPS Research

**Fig 2 – DABUR**

(Rs mn)	Q3FY24E	Q2FY24	Q3FY23	QoQ (%)	YoY (%)	Remarks
Revenue	32,813	32,038	30,432	2.4	7.8	We expect DABUR to report high-single-digit revenue growth during the quarter backed by a consistent volume uptick in both urban as well as rural markets. Early management commentary suggests mid-to-high-single-digit volume growth across the portfolio, except the healthcare business which was affected by a delay in onset of the winter season.
Gross Profit	15,717	15,482	13,850	1.5	13.5	
Gross Profit Margin (%)	47.9	48.3	45.5	(40bps)	240bps	
EBITDA	6,759	6,609	6,099	2.3	10.8	
EBITDA Margin (%)	20.6	20.6	20.0	0bps	60bps	
Adj. PAT	5,243	5,151	4,759	1.8	10.2	
Adj. PAT Margin (%)	16.0	16.1	15.6	(10bps)	40bps	

Source: Company, BOBCAPS Research

**Fig 3 – HUVR**

(Rs mn)	Q3FY24E	Q2FY24	Q3FY23	QoQ (%)	YoY (%)	Remarks
Revenue	159,312	156,230	155,970	2.0	2.1	HUVR is forecast to report just 2.1% YoY value growth in Q3FY24 owing to soft volume growth (~2%) across the portfolio. General trade has been flattish during the quarter due to stress in the mass segment. We expect gross margin to improve by 360bps YoY led by favorable RM prices and cost rationalisation initiatives taken by the company. HUVR continues to focus on premiumisation in its core portfolio which is likely to aid sustained market share gains.
Gross Profit	82,205	82,780	74,890	(0.7)	9.8	
Gross Profit Margin (%)	51.6	53.0	48.0	(140bps)	360bps	
EBITDA	37,120	37,970	36,940	(2.2)	0.5	
EBITDA Margin (%)	23.3	24.3	23.0	(100bps)	30bps	
Adj. PAT	26,262	26,610	25,770	(1.3)	1.9	
Adj. PAT Margin (%)	16.5	17.0	16.5	(50bps)	0bps	

Source: Company, BOBCAPS Research

**Fig 4 – ITC**

(Rs mn)	Q3FY24E	Q2FY24	Q3FY23	QoQ (%)	YoY (%)	Remarks
Revenue	183,995	177,745	177,045	3.5	3.9	We expect ITC to report mid-single-digit volume growth in its cigarette portfolio. The FMCG business is projected to record strong double-digit growth with expansion in margins. Hotels should continue to perform well on higher occupancy and RevPAR. The paper and paperboard business continues to suffer from the impact of volatility in pulp prices and Chinese competition.
Gross Profit	110,067	107,058	108,090	2.8	1.8	
Gross Profit Margin (%)	59.8	60.2	61.1	(40bps)	(130bps)	
EBITDA	66,460	64,542	67,047	3.0	(0.9)	
EBITDA Margin (%)	36.1	36.3	35.5	(20bps)	60bps	
Adj. PAT	50,198	48,981	50,067	2.5	0.3	
Adj. PAT Margin (%)	27.3	27.4	28.3	(10bps)	(100bps)	

Source: Company, BOBCAPS Research | RevPAR: Revenue Per Available Room

**Fig 5 – MRCO**

(Rs mn)	Q3FY24E	Q2FY24	Q3FY23	QoQ (%)	YoY (%)	Remarks
Revenue	24,181	24,760	24,700	(2.3)	(2.1)	We forecast a 2.1% YoY decline in revenue for MRCO owing to price correction and muted volume growth in the domestic market. The company expects to report low-single-digit volume growth in <i>Parachute</i> oil and <i>Saffola</i> edible oil and low-single-digit value growth in value-added hair oil (VAHO). For the international business, management expects to deliver mid-single-digit revenue growth in constant currency terms.
Gross Profit	12,221	12,260	11,780	(0.3)	3.7	
Gross Profit Margin (%)	49.2	50.5	44.9	(130bps)	430bps	
EBITDA	5,172	4,970	4,560	4.1	13.4	
EBITDA Margin (%)	21.5	20.1	18.5	140bps	300bps	
Adj. PAT	3,753	3,530	3,280	6.3	14.4	
Adj. PAT Margin (%)	15.6	14.3	13.3	130bps	230bps	

Source: Company, BOBCAPS Research

**Fig 6 – NEST**

(Rs mn)	Q4CY23E	Q3CY23	Q4CY22	QoQ (%)	YoY (%)	Remarks
Revenue	47,877	50,368	42,568	(4.9)	12.5	We project revenue growth of 12.5% YoY for NEST during Q3FY24 driven by a healthy mix of pricing and volumes. We believe the company will drive growth in rural markets as it continues to expand its presence. Gross margin is expected to expand 190bps YoY due to softer input cost. Management commentary on volume growth, new product launches and market penetration remains key to watch.
Gross Profit	27,194	28,452	23,353	(4.4)	16.4	
Gross Profit Margin (%)	56.8	56.5	54.9	30bps	190bps	
EBITDA	12,017	12,249	9,730	(1.9)	23.5	
EBITDA Margin (%)	25.1	24.3	22.9	80bps	220bps	
Adj. PAT	7,874	9,081	6,281	(13.3)	25.4	
Adj. PAT Margin (%)	16.5	18.0	14.8	(158bps)	170bps	

Source: Company, BOBCAPS Research

**Fig 7 – ZYWL**

(Rs mn)	Q3FY24E	Q2FY24	Q3FY23	QoQ (%)	YoY (%)	Remarks
Revenue	4,314	4,399	4,156	(1.9)	3.8	We estimate that ZYWL will report revenue growth of 3.8% YoY in a seasonally weak quarter. Gross profit is forecast to grow by 4.8% with margin expansion of 40bps YoY. Volume growth and market share gains in the food & nutrition category remain key aspects to monitor.
Gross Profit	1,911	1,987	1,823	(3.8)	4.8	
Gross Profit Margin (%)	44.3	45.2	43.9	(90bps)	40bps	
EBITDA	298	168	282	77.4	5.7	
EBITDA Margin (%)	6.9	3.8	6.8	310bps	10bps	
Adj. PAT	226	59	196	283.1	15.3	
Adj. PAT Margin (%)	5.2	1.3	4.7	390bps	50bps	

Source: Company, BOBCAPS Research

**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

**Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

**Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

**Distribution into the United Kingdom ("UK"):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

**No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

**Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.